VitriVax, headquartered in Boulder, Colorado, is a vaccine formulation technology company that engineers innovative solutions to maximize global accessibility and utility of human vaccines - vaccines that save lives and protect our world from preventable disease.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/22/25 | $17,250,000 | Series B |
Adjuvant Capital RA Capital Management | undisclosed |
